1. Bray F, Ferlay J, Soerjomataram I, et al. (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 68: 394-424. [DOI:10.3322/caac.21492]

2. Lagergren J, Smyth E, Cunningham D, Lagergren P (2017) Oesophageal cancer. Lancet, 390: 2383-2396. [DOI:10.1016/S0140-6736(17)31462-9]

3. Rice TW, Chen LQ, Hofstetter WL, et al. (2016) Worldwide Esophageal Cancer Collaboration: pathologic staging data. Dis Esophagus, 29: 724-733. [DOI:10.1111/dote.12520]

4. Puli SR, Reddy JB, Bechtold ML, et al. (2008) Staging accuracy of esophageal cancer by endoscopic ultrasound: a meta-analysis and systematic review. World J Gastroenterol, 14: 1479-1490. [DOI:10.3748/wjg.14.1479]

5. Shi W, Wang W, Wang J, et al. (2013) Meta-analysis of 18FDG PET-CT for nodal staging in patients with esophageal cancer. Surg Oncol, 22: 112-116. [DOI:10.1016/j.suronc.2013.02.003]

6. Pan L, Gu P, Huang G, et al. (2009) Prognostic significance of SUV on PET/CT in patients with esophageal cancer: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol, 21: 1008-1015. [DOI:10.1097/MEG.0b013e328323d6fa]

7. Chatterton BE, Ho SI, Baldey A, et al. (2009) Positron emission tomography changes management and prognostic stratification in patients with oesophageal cancer: results of a multicentre prospective study. Eur J Nucl Med Mol Imaging, 36: 354-361. [DOI:10.1007/s00259-008-0959-y]

8. Yap WK, Chang YC, Tseng CK, et al. (2017) Predictive value of nodal maximum standardized uptake value of pretreatment [18F]fluorodeoxyglucose positron emission tomography imaging in patients with esophageal cancer. Dis Esophagus, 30: 1-10. [DOI:10.1093/dote/dox021]

9. Inokuchi H, Kodaira T, Tachibana H, et al. (2011) Clinical usefulness of [18F] fluoro-2-deoxy-D-glucose uptake in 178 head-and-neck cancer patients with nodal metastasis treated with definitive chemoradiotherapy: consideration of its prognostic value and ability to provide guidance for optimal selection of patients for planned neck dissection. Int J Radiat Oncol Biol Phys, 79: 747-755. [DOI:10.1016/j.ijrobp.2009.11.034]

10. Camp RL, Dolled-Filhart M, Rimm DL (2004) X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res, 10: 7252-7259. [DOI:10.1158/1078-0432.CCR-04-0713]

11. Meignan M, Cottereau AS, Versari A, et al. (2016) Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: A pooled analysis of three multicenter studies. J Clin Oncol, 34: 3618-3626. [DOI:10.1200/JCO.2016.66.9440]

12. Chin AL, Kumar KA, Guo HH, et al. (2018) Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non-Small-cell Lung Cancer. Clin Lung Cancer, 19: e581-e588. [DOI:10.1016/j.cllc.2018.04.003]

13. Sharma A, Mohan A, Bhalla AS et al. (2018) Role of various metabolic parameters derived from baseline 18F-FDG PET/CT as prognostic markers in non-small cell lung cancer patients undergoing platinum-based chemotherapy. Clin Nucl Med, 43: e8-e17. [DOI:10.1097/RLU.0000000000001886]

14. Hyun SH, Choi JY, Shim YM, et al. (2010) Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma. Ann Surg Oncol, 17: 115-122. [DOI:10.1245/s10434-009-0719-7]

15. Nakajo M, Jinguji M, Nakabeppu Y, et al. (2017) Texture analysis of (18)F-FDG PET/CT to predict tumour response and prognosis of patients with esophageal cancer treated by chemoradiotherapy. Eur J Nucl Med Mol Imaging, 44: 206-214. [DOI:10.1007/s00259-016-3506-2]

16. Rizk NP, Tang L, Adusumilli PS, et al. (2009) Predictive value of initial PET-SUVmax in patients with locally advanced esophageal and gastroesophageal junction adenocarcinoma. J Thorac Oncol, 4: 875-879. [DOI:10.1097/JTO.0b013e3181a8cebf]

17. Yap WK, Chang YC, Tseng CK, et al. (2017) Predictive value of nodal maximum standardized uptake value of pretreatment [18F]fluorodeoxyglucose positron emission tomography imaging in patients with esophageal cancer. Dis Esophagus, 30: 1-10. [DOI:10.1093/dote/dox021]

18. Kubicek GJ, Champ C, Fogh S, et al. (2010) FDG-PET staging and importance of lymph node SUV in head and neck cancer. Head Neck Oncol, 2: 19. [DOI:10.1186/1758-3284-2-19]

19. Kato H and Nakajima M (2012) The efficacy of FDG-PET for the management of esophageal cancer: review article. Ann Thorac Cardiovasc Surg, 18: 412-419. [DOI:10.5761/atcs.ra.12.01954]

20. Li B, Li N, Liu S, et al. (2020) Does [18F] fluorodeoxyglucose-positron emission tomography/computed tomography have a role in cervical nodal staging for esophageal squamous cell carcinoma? J Thorac Cardiovasc Surg, 160: 544-550. [DOI:10.1016/j.jtcvs.2019.11.046]

21. Yasuda T, Higuchi I, Yano M et al.(2012) The impact of (1)(8)F-fluorodeoxyglucose positron emission tomography positive lymph nodes on postoperative recurrence and survival in resectable thoracic esophageal squamous cell carcinoma. Ann Surg Oncol, 19: 652-660. [DOI:10.1245/s10434-011-1928-4]

22. Nagaki Y, Motoyama S, Sato Y, et al. (2022) PET-uptake reduction into lymph nodes after neoadjuvant therapy is highly predictive of prognosis for patients who have thoracic esophageal squamous cell carcinoma treated with chemoradiotherapy plus esophagectomy. Ann Surg Oncol, 29: 1336-1346. [DOI:10.1245/s10434-021-10564-3]

23. Lee JY, Kim YH, Park YJ, et al. (2019) Improved detection of metastatic lymph nodes in oesophageal squamous cell carcinoma by combined interpretation of fluorine-18-fluorodeoxyglucose positron-emission tomography/computed tomography. Cancer Imaging, 19: 40. [DOI:10.1186/s40644-019-0225-5]

24. Xia L, Li X, Zhu J et al. (2023) Prognostic value of baseline (18)F-FDG PET/CT in patients with esophageal squamous cell carcinoma treated with definitive (chemo)radiotherapy. Radiat Oncol, 18: 41. [DOI:10.1186/s13014-023-02224-5]